Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9611267 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jan, 2035
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10131667 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jun, 2033
(9 years from now) | |
US11466004 | INCYTE CORP | Solid forms of an FGFR inhibitor and processes for preparing the same |
May, 2039
(15 years from now) | |
US11628162 | INCYTE CORP | Methods of treating cancer with an FGFR inhibitor |
Aug, 2040
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
Orphan Drug Exclusivity(ODE-292) | Apr 17, 2027 |
Orphan Drug Exclusivity(ODE-404) | Aug 26, 2029 |
New Indication(I-899) | Aug 26, 2025 |
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement; Treatment of p...
Dosage: TABLET;ORAL